CoChat
Sign Up
Cited by 282Pluripotent Stem Cells ResearchSkin and Cellular Biology ResearchHair Growth and Disorders

Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells

Open access
Itoh, Munenari, Kiuru, Maija, Cairo, Mitchell S., Christiano, Angela M.·2011·Proceedings of the National Academy of Sciences
DOI 10.1073/pnas.1100332108PMC PMC3102348
Open this paper in CoChat — free account

Abstract

Embryonic stem cells (ESCs) have an unlimited proliferative capacity and extensive differentiation capability. They are an alternative source for regenerative therapies with a potential role in the treatment of several human diseases. The clinical use of ESCs, however, has significant ethical and biological obstacles related to their derivation from embryos and potential for immunological rejection, respectively. These disadvantages can be circumvented by the alternative use of induced pluripotent stem cells (iPSCs), which are generated from an individual's (autologous) somatic cells by exogenous expression of defined transcription factors and have biological characteristics similar to ESCs. In recent years, patient-specific iPSCs have been generated to study disease mechanisms and develop iPSC-based therapies. The development of iPSC-based therapies for skin diseases requires successful differentiation of iPSCs into cellular components of the skin, including epidermal keratinocytes. Here, we succeeded in generating iPSCs not only from normal human fibroblasts but also from fibroblasts isolated from the skin of two patients with recessive dystrophic epidermolysis bullosa. Moreover, we differentiated both of these iPSCs into keratinocytes with high efficiency, and generated 3D skin equivalents using iPSC-derived keratinocytes, suggesting that they were fully functional. Our studies indicate that autologous iPSCs have the potential to provide a source of cells for regenerative therapies for specific skin diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1100332108

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Skin organoids can be readily generated from patient-derived cells and used to model genetic disorders, such as epidermolysis bullosa.

    “Furthermore, skin organoids can be readily generated from patient-derived cells and used to model genetic disorders, such as epidermolysis bullosa”

    From Generation and characterization of hair-bearing skin organoids from human pluripotent stem cells (2022) · cites this paper as [62]

    The Results and Discussion (pages not provided) show that the authors generated 3D skin equivalents from cells derived from patients with recessive dystrophic epidermolysis bullosa and used them as in vitro disease models. The paper calls these constructs skin equivalents, not organoids, and describes a multistep construction protocol; it does not establish that skin organoids can be readily generated. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 33 · Cited by 282

Research works printed but not linked: 29

  1. [1]Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–872. doi: 10.1016/j.cell.2007.11.019. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  2. [2]Jones JM, Thomson JA. Human embryonic stem cell technology. Semin Reprod Med. 2000;18:219–223. doi: 10.1055/s-2000-12560. [DOI] [PubMed] [Google Scholar] · DOI
  3. [5]Raya A, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature. 2009;460:53–59. doi: 10.1038/nature08129. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  4. [6]Lee G, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature. 2009;461:402–406. doi: 10.1038/nature08320. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  5. [7]Hanna J, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007;318:1920–1923. doi: 10.1126/science.1152092. [DOI] [PubMed] [Google Scholar] · DOI
  6. [8]Uitto J, McGrath JA, Rodeck U, Bruckner-Tuderman L, Robinson EC. Progress in epidermolysis bullosa research: Toward treatment and cure. J Invest Dermatol. 2010;130:1778–1784. doi: 10.1038/jid.2010.90. [DOI] [PubMed] [Google Scholar] · DOI
  7. [9]McGrath JA, Schofield OM, Mayou BJ, McKee PH, Eady RA. Epidermolysis bullosa complicated by squamous cell carcinoma: Report of 10 cases. J Cutan Pathol. 1992;19:116–123. doi: 10.1111/j.1600-0560.1992.tb01352.x. [DOI] [PubMed] [Google Scholar] · DOI
  8. [10]Pham C, Greenwood J, Cleland H, Woodruff P, Maddern G. Bioengineered skin substitutes for the management of burns: A systematic review. Burns. 2007;33:946–957. doi: 10.1016/j.burns.2007.03.020. [DOI] [PubMed] [Google Scholar] · DOI
  9. [11]Titeux M, et al. SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa. Mol Ther. 2010;18:1509–1518. doi: 10.1038/mt.2010.91. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  10. [12]Mavilio F, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med. 2006;12:1397–1402. doi: 10.1038/nm1504. [DOI] [PubMed] [Google Scholar] · DOI
  11. [13]Green H, Easley K, Iuchi S. Marker succession during the development of keratinocytes from cultured human embryonic stem cells. Proc Natl Acad Sci USA. 2003;100:15625–15630. doi: 10.1073/pnas.0307226100. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  12. [14]Metallo CM, Ji L, de Pablo JJ, Palecek SP. Retinoic acid and bone morphogenetic protein signaling synergize to efficiently direct epithelial differentiation of human embryonic stem cells. Stem Cells. 2008;26:372–380. doi: 10.1634/stemcells.2007-0501. [DOI] [PubMed] [Google Scholar] · DOI
  13. [15]Guenou H, et al. Human embryonic stem-cell derivatives for full reconstruction of the pluristratified epidermis: A preclinical study. Lancet. 2009;374:1745–1753. doi: 10.1016/S0140-6736(09)61496-3. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  14. [16]Bain G, Kitchens D, Yao M, Huettner JE, Gottlieb DI. Embryonic stem cells express neuronal properties in vitro. Dev Biol. 1995;168:342–357. doi: 10.1006/dbio.1995.1085. [DOI] [PubMed] [Google Scholar] · DOI
  15. [17]Gambaro K, Aberdam E, Virolle T, Aberdam D, Rouleau M. BMP-4 induces a Smad-dependent apoptotic cell death of mouse embryonic stem cell-derived neural precursors. Cell Death Differ. 2006;13:1075–1087. doi: 10.1038/sj.cdd.4401799. [DOI] [PubMed] [Google Scholar] · DOI
  16. [18]Ortiz-Urda S, et al. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest. 2003;111:251–255. doi: 10.1172/JCI17193. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  17. [19]Chen M, et al. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet. 2002;32:670–675. doi: 10.1038/ng1041. [DOI] [PubMed] [Google Scholar] · DOI
  18. [20]Gache Y, et al. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Hum Gene Ther. 2004;15:921–933. doi: 10.1089/hum.2004.15.921. [DOI] [PubMed] [Google Scholar] · DOI
  19. [21]Kiuru M, Itoh M, Cairo MS, Christiano AM. Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa. Dermatol Clin. 2010;28:371–382. doi: 10.1016/j.det.2010.02.004. xii–xiii. [DOI] [PubMed] [Google Scholar] · DOI
  20. [22]Wagner JE, et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med. 2010;363:629–639. doi: 10.1056/NEJMoa0910501. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  21. [23]Tolar J, et al. Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2011;131:848–856. doi: 10.1038/jid.2010.346. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  22. [24]Bilousova G, Chen J, Roop DR. Differentiation of mouse induced pluripotent stem cells into a multipotent keratinocyte lineage. J invest Dermatol. 2011;131:857–864. doi: 10.1038/jid.2010.364. [DOI] [PubMed] [Google Scholar] · DOI
  23. [25]Regauer S, Seiler GR, Barrandon Y, Easley KW, Compton CC. Epithelial origin of cutaneous anchoring fibrils. J Cell Biol. 1990;111:2109–2115. doi: 10.1083/jcb.111.5.2109. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  24. [26]Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448:313–317. doi: 10.1038/nature05934. [DOI] [PubMed] [Google Scholar] · DOI
  25. [27]Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science. 2008;322:949–953. doi: 10.1126/science.1164270. [DOI] [PubMed] [Google Scholar] · DOI
  26. [28]Kim D, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009;4:472–476. doi: 10.1016/j.stem.2009.05.005. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  27. [29]Kaji K, et al. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature. 2009;458:771–775. doi: 10.1038/nature07864. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  28. [32]Jonkman MF. Revertant mosaicism in human genetic disorders. Am J Med Genet. 1999;85:361–364. doi: 10.1002/(sici)1096-8628(19990806)85:4<361::aid-ajmg11>3.0.co;2-e. [DOI] [PubMed] [Google Scholar] · DOI
  29. [33]Pasmooij AM, Pas HH, Bolling MC, Jonkman MF. Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3. J Clin Invest. 2007;117:1240–1248. doi: 10.1172/JCI30465. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI

Authors
Itoh, M., Kiuru, M., Cairo, M. S., & Christiano, A. M.
Affiliations
  • Columbia University Irving Medical Center (US)
  • Columbia University (US)
ORCID
Venue
Proceedings of the National Academy of Sciences
Publisher
National Academy of Sciences
Published
2011-05-09
Volume
108
Issue
21
Pages
8797-8802
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
DOI
10.1073/pnas.1100332108
PMC
PMC3102348
OpenAlex
W2120299070
Cited by
282
References
33
Citations by year
2026: 3 · 2025: 7 · 2024: 13 · 2023: 12 · 2022: 16 · 2021: 20 · 2020: 24 · 2019: 14 · 2018: 16 · 2017: 24 · 2016: 18 · 2015: 19 · 2014: 34 · 2013: 28 · 2012: 28
FWCI
12.45
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • New York State Stem Cell Science
  • National Institutes of Health
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR044535)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Skin and Cellular Biology Research
  • Health Sciences › Medicine › Urology › Hair Growth and Disorders
Keywords
induced pluripotent stem cells, keratinocytes, recessive dystrophic epidermolysis bullosa, keratinocyte differentiation, 3D skin equivalents, iPSC-based therapy, skin diseases, autologous cell therapy, fibroblasts, regenerative therapy
MeSH terms
Cell Differentiation, Fibroblasts, Humans, Skin Diseases, Keratinocytes, Epidermolysis Bullosa Dystrophica, Cell Culture Techniques, Regenerative Medicine, Induced Pluripotent Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review